A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Must have received: standard of care therapy — for tumor type and stage of disease

Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy.

Cannot have received: nitrosourea

Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment

Cannot have received: mitomycin C

Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment

Cannot have received: investigational agents or study drugs

Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose of study treatment

Cannot have received: cytotoxic chemotherapy

Cytotoxic treatment: 21 days prior to the first dose of study intervention

Cannot have received: non-cytotoxic drugs

Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter) prior to the first dose of study intervention

Cannot have received: biological products including immuno-oncology agents

Biological products including immuno-oncology agents: 28 days prior to the first dose of study intervention

Cannot have received: TOP1 inhibitor (irinotecan, topotecan, trastuzumab deruxtecan)

Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)

Cannot have received: PARP inhibitor (AZD9574)

Exception: more than 1 prior line of any other PARPi-based regimen

Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen

Cannot have received: rilvegostomig (rilvegostomig)

Previous treatment with rilvegostomig for the cohort treated with rilvegostomig